Otros idiomas TaiMed Biologics Inc.

Acciones

4147

TW0004147004

Biotecnología e investigación médica

Precio de cierre Taipei Exchange Otros sitios de cotización 05/12/2025			Variación 5 días	Varia. 1 de enero.
67,40 ^TWD	-1,75 %		-1,17 %	-21,63 %

12/11	TaiMed Biologics Inc. presenta resultados financieros del tercer trimestre y de los nueve meses finalizados el 30 de septiembre de 2025	CI
12/08	TaiMed Biologics Inc. presenta resultados financieros del segundo trimestre y primer semestre finalizados el 30 de junio de 2025	CI

Otros idiomas

TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	12/11
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	12/08
TaiMed Biologics Inc. Initiates Phase 2b Clinical Study Preparation of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection	22/06
TaiMed Biologics Inc. Announces Election of New Chairperson Effective June 4, 2025	04/06
TaiMed Biologics Inc. Announces Retirement of Jack Chen as Financial Officer/ CFO, Effective June 04, 2025	04/06
TaiMed Biologics Inc. Approves Board Elections	03/06
TaiMed Biologics Inc. Announces Application to the US FDA for Phase 2b Study of the Combination of TMB-365/380 as Maintenance Therapy in HIV-1	21/05
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	12/05
TaiMed Biologics Inc. Signs CDMO Service Agreement with U.S. Client, Adding Growth Momentum to Operations	30/04
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	14/03
TaiMed Biologics Inc. Presents Data from the PROMISE-US Trial of Ibalizumab at CROI	13/03
Taimed Biologics Inc. Presents Late-Breaking Phase Iiadata At Croi 2025 on Long-Acting Tmb-365/Tmb-380 Regimenfor Hiv Maintenance Therapy	12/03
TaiMed Biologics Inc. Announces Phase 2A Clinical Study Results of Long-Acting TMB-365/TMB-380 Combination Therapy Have Been Accepted to Present at CROI 2025 Annual Conference	21/01
Taimed Biologics Announces Its Long-Acting Tmb-365/380 Monoclonal Antibody Combination Hiv Therapy Meets All Primary Endpoints in Phase 2A Clinical Study	07/01
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	13/11
TaiMed Biologics Inc. Secures its First CDMO Contract from an International Client	29/10/24
Taimed Biologics Inc. Receives Patent Approval from China for Improving the Pharmacokinetic Performance of Tmb-365 Using Histidine Modification Technology	26/10/24
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	14/08/24
TaiMed Biologics Inc. Receives Patent Approval from the US PTO for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology	18/07/24
Orient Europharma Co., Ltd. Signs an Exclusive Sales and Marketing Agreement for the New AIDS Drug Trogarzo in Taiwan with Taimed Biologics	20/05/24
TaiMed Biologics Inc. and Orient EuroPharma Company Limited Signs Trogarzo Commercial License Agreement in Taiwan	20/05/24
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05/24
TaiMed Biologics Inc. Announces Enrollment of the Last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 Mabcombination for the Bi-Monthly Maintenance HIV Therapy	10/05/24
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03/24
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	13/03/24

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas TaiMed Biologics Inc.

Acciones

4147

TW0004147004

Biotecnología e investigación médica

Otros idiomas

Filtros